SGLT2 inhibitor
SGLT2 Inhibitor
SGLT2 inhibitors (pronounced as S-G-L-T-two inhibitors), also known as sodium-glucose co-transporter 2 inhibitors, are a class of medications used primarily in the treatment of type 2 diabetes.
Etymology
The term "SGLT2 inhibitor" is derived from the name of the protein that these drugs inhibit, the Sodium-Glucose co-Transporter 2 (SGLT2). This protein is responsible for the reabsorption of glucose in the kidney, and by inhibiting it, these drugs reduce the amount of glucose reabsorbed, leading to a reduction in blood glucose levels.
Mechanism of Action
SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, which is then excreted in the urine. This leads to a decrease in blood glucose levels, helping to manage hyperglycemia (high blood sugar) in people with type 2 diabetes.
Related Terms
- Gliflozins: This is a class of drugs that includes all SGLT2 inhibitors. They are also known as "glucose eliminators" because they work by eliminating excess glucose through the urine.
- Dapagliflozin: This is a specific type of SGLT2 inhibitor. It is marketed under the brand name Farxiga.
- Canagliflozin: Another specific type of SGLT2 inhibitor, marketed under the brand name Invokana.
- Empagliflozin: This is another specific type of SGLT2 inhibitor, marketed under the brand name Jardiance.
Side Effects
Like all medications, SGLT2 inhibitors can have side effects. These can include urinary tract infections, increased urination, and in rare cases, a serious condition called diabetic ketoacidosis.
See Also
External links
- Medical encyclopedia article on SGLT2 inhibitor
- Wikipedia's article - SGLT2 inhibitor
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski